Price$164.08+1.04 (+0.64%)
01:30 PM07:45 PM
News · 26 weeks820%
2026-01-182026-07-12
Mix4090d
- Insider16(40%)
- Other12(30%)
- SEC Filings6(15%)
- Analyst3(8%)
- Earnings2(5%)
- Leadership1(3%)
Latest news
25 items- PRInsulet Partners with Calm to Bring Mindfulness and Well-Being Tools to the Diabetes Community, Featuring a New Sleep Story Narrated by Lila MossThe partnership introduces The Mind in Range Collection, a set of tailored mindfulness resources available at no cost to the diabetes community, including a meditation series, a breathing exercise, and a new Calm Sleep Story narrated by Omnipod® user and fashion model Lila Moss, designed to help listeners unwind and feel supported With 359 million people worldwide living with an anxiety disorder1, and people with diabetes being 20% more likely to develop anxiety2, this initiative reinforces Insulet’s commitment to whole-person care and positions mental health as essential to diabetes management The integrated content collaboration is the first-of-its-kind between Calm and a MedTe
- INSIDERAmendment: Director Huffines Robert Luther was granted 151 shares, increasing direct ownership by 7% to 2,449 units (SEC Form 4)4/A - INSULET CORP (0001145197) (Issuer)
- PRInsulet Accelerates Global Growth with Launch of Omnipod® 5 and Omnipod Discover™ in Spain, Expanding Access to Tubeless Diabetes TechnologyOmnipod 5 Automated Insulin Delivery System now available in 20 countries worldwide New web-based data platform Omnipod Discover simplifies diabetes insights for users, caregivers, and healthcare professionals Omnipod 5 launch in Spain is compatible with Abbott and Dexcom continuous glucose monitoring systems Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the commercial launch of its Omnipod 5 Automated Insulin Delivery System and its proprietary data management system Omnipod Discover™ in Spain, the Company’s newest European market. Spain is the 26th country whe
- INSIDERDirector Mazelsky Jonathan Jay was granted 1,355 shares (SEC Form 4)4 - INSULET CORP (0001145197) (Issuer)
- INSIDERNew insider Mazelsky Jonathan Jay claimed no ownership of stock in the company (SEC Form 3)3 - INSULET CORP (0001145197) (Issuer)
- INSIDERDirector Huffines Robert Luther was granted 144 shares, increasing direct ownership by 6% to 2,442 units (SEC Form 4)4 - INSULET CORP (0001145197) (Issuer)
- PRInsulet to Announce Second Quarter 2026 Financial Results on August 5, 2026Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the second quarter of 2026 on Wednesday, August 5, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or
- SECInsulet Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - INSULET CORP (0001145197) (Filer)
- PRInsulet Announces Appointment of Jonathan J. Mazelsky to its Board of DirectorsInsulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Jonathan ("Jay") Mazelsky to the Company’s Board of Directors, effective July 1, 2026. Mr. Mazelsky joins the Board as an independent director. "We are pleased to welcome Jay to Insulet’s Board of Directors," said President and CEO Ashley McEvoy. "Jay has a strong track record of translating science into solutions to drive growth and create significant and enduring shareholder value. His background and expertise will be integral as Insulet continues to expand access and further strengthen Omnipod’s leaders
- ANALYSTDeutsche Bank initiated coverage on Insulet with a new price targetDeutsche Bank initiated coverage of Insulet with a rating of Buy and set a new price target of $190.00
- PRInsulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to CareSTRIVE pivotal trial shows Omnipod 6 achieved strong glycemic outcomes with fewer boluses, across age groups and diabetes types EVOLUTION 3 feasibility study demonstrates improved time in range using a fully closed-loop system for type 2 diabetes that automatically adjusts insulin with no user settings Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced new clinical results highlighting the next breakthroughs in tubeless Automated Insulin Delivery (AID) systems. The data and growing body of evidence not only confirm the impact of Insulet's technology today—it also fuels
- INSIDERDirector Stonesifer Timothy C. bought $400,393 worth of shares (2,790 units at $143.51), increasing direct ownership by 45% to 9,041 units (SEC Form 4)4 - INSULET CORP (0001145197) (Issuer)
- INSIDERDirector Borio Luciana sold $59,887 worth of shares (418 units at $143.27), decreasing direct ownership by 9% to 4,329 units (SEC Form 4)4 - INSULET CORP (0001145197) (Issuer)
- PRInsulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at the American Diabetes Association 86th Scientific SessionsPresentations will feature next generation Omnipod innovations designed to reduce user effort, new algorithm data, and clinical evidence demonstrating improved time in range Insulet-led sessions will highlight how patient-centered design and strong clinical performance is helping redefine Automated Insulin Delivery (AID) across type 1 and type 2 diabetes Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its planned activities during the American Diabetes Association (ADA) 86th Scientific Sessions, taking place June 5 – 8, 2026 in New Orleans. "At Insulet, we believe
- INSIDERDirector Weatherman Elizabeth H bought $497,490 worth of shares (3,450 units at $144.20), increasing direct ownership by 50% to 10,352 units (SEC Form 4)4 - INSULET CORP (0001145197) (Issuer)
- PRInsulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott's FreeStyle Libre 3 Plus SensorEnhanced algorithm with new 100 mg/dL Target Glucose and improved alarm handling helps users improve time in range and stay in Automated Mode longer Omnipod 5 is now compatible with Abbott's Libre 3 Plus sensor in U.S., giving users more choice in how they manage their diabetes New features are designed to improve outcomes, reduce diabetes burden, and unlock barriers to AID technology to meet the needs of people with diabetes Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the U.S. rollout of new algorithm enhancements for the Omnipod 5 Automated Insulin Delivery
- SECSEC Form SD filed by Insulet CorporationSD - INSULET CORP (0001145197) (Filer)
- PRInsulet to Participate in William Blair 46th Annual Growth Stock ConferenceInsulet Corporation (NASDAQ:PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the William Blair 46th Annual Growth Stock Conference in Chicago on Wednesday, June 3, 2026 at 2:00 p.m. (Central Time). The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events. About Insulet Corporation: Insulet Corporation (NASDAQ:PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipo
- SECInsulet Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - INSULET CORP (0001145197) (Filer)
- PRInsulet Initiates Voluntary Medical Device Correction for Certain Omnipod® Pods in the U.S. and Affected International MarketsInsulet Corporation, Inc. (NASDAQ:PODD) ("Insulet" or the "Company") today announced a voluntary Medical Device Correction for specific lots of Omnipod® 5, Omnipod DASH®, and Omnipod® Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delivery. This action is separate from the voluntary Medical Device Correction issued on March 12, 2026 affecting certain Omnipod 5 Pods in the U.S. and includes certain Pod lots distributed in the U.S. and affected international markets. Pods not included in the affected lots remain safe to use. Insulet identified that some Pods from specific lots ma
- INSIDERDirector Weatherman Elizabeth H was granted 1,660 shares, increasing direct ownership by 32% to 6,902 units (SEC Form 4)4 - INSULET CORP (0001145197) (Issuer)
- INSIDERDirector Stonesifer Timothy C. was granted 1,660 shares, increasing direct ownership by 36% to 6,251 units (SEC Form 4)4 - INSULET CORP (0001145197) (Issuer)
- INSIDERDirector Scannell Timothy J was granted 1,660 shares, increasing direct ownership by 5% to 33,024 units (SEC Form 4)4 - INSULET CORP (0001145197) (Issuer)
- INSIDERDirector Minogue Michael R was granted 1,660 shares, increasing direct ownership by 213% to 2,438 units (SEC Form 4)4 - INSULET CORP (0001145197) (Issuer)
- INSIDERDirector Huffines Robert Luther was granted 1,660 shares, increasing direct ownership by 260% to 2,298 units (SEC Form 4)4 - INSULET CORP (0001145197) (Issuer)
PODD FAQ
7 questionsWhat does Insulet Corporation do?
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.Where does PODD stock trade?
Insulet Corporation (PODD) is listed on NASDAQ.What sector and industry is PODD in?
Insulet Corporation operates in the Health Care sector, Medical/Dental Instruments industry.When did Insulet Corporation go public?
Insulet Corporation (PODD) completed its IPO in 2007.What are analysts saying about PODD?
Insulet Corporation has had 8 recent analyst actions on file. The most recent action was from Deutsche Bank: Buy on 2026-06-23.What companies are similar to PODD?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare PODD side-by-side with any of them on Quantisnow.How can I track PODD on Quantisnow?
Quantisnow aggregates Insulet Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PODD to receive live email and push alerts on every new disclosure.